Nicox and partner Ocumension submit NDA for NCX 470 in China, targeting approval for a novel nitric oxide-donating glaucoma therapy
Executive summary: Ocumension, Nicox’s partner in Greater China, submitted a New Drug Application (NDA) for NCX 470 to China’s NMPA on August 10, 2026. This submission is a pivotal step toward potential approval of NCX 470, a novel glaucoma therapy, in the world’s second-largest pharmaceutical market.
Who is involved: Nicox (developer), Ocumension (China partner), and China’s National Medical Products Administration (NMPA) as the regulatory authority.
Likely next: NMPA review and potential approval within 12 months; if successful, Ocumension would initiate commercial launch in China.
Nicox announced that its partner Ocumension has submitted a New Drug Application (NDA) for NCX 470 to China’s National Medical Products Administration (NMPA). NCX 470 is a proprietary nitric oxide-donating bimatoprost ophthalmic solution being developed for the treatment of glaucoma and ocular hypertension. The submission marks a key regulatory milestone in Nicox’s strategy to commercialize the asset in Greater China through its partnership with Ocumension, which holds exclusive rights for the territory. If approved, NCX 470 would represent a differentiated treatment option in a large and growing market.
Timeline
- — Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension (GlobeNewswire)
- — Alebund's AP301 NDA Accepted for Review by China's NMPA (PR Newswire)
Analysis — what this means
Likely next events
- NMPA acceptance review completion expected by Q4 2026
- Potential NMPA approval decision by Q3 2027
- Ocumension to begin commercial preparation in China upon approval
Sectors affected
- Ophthalmic pharmaceuticals
- Glaucoma therapeutics
- China biopharmaceutical market
Regulatory implications
- NMPA review timelines for NDAs typically range from 10 to 15 months
- Approval would require compliance with Chinese GMP and post-marketing study requirements
- NCX 470 may be eligible for priority review under China’s innovative drug pathways if clinical superiority is demonstrated
Historical parallels
- Similar to Aerie Pharmaceuticals’ NDA submission for Rhopressa in China in 2021, which faced delays due to additional local trial requirements
- Parallel to Nicox’s own NCX 470 NDA submission in the EU in 2023, which is still under EMA review
- Comparable to Alebund’s AP301 NDA acceptance by NMPA in August 2026 for a renal phosphate binder
Key entities
Sources
Open the full interactive case file on Beyond →